

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of March 2018**

	<b>31.03.2018</b>	<b>31.12.2017</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	26 268	26 803
Intangible assets	3 067	2 998
Investment in minority interest	1	1
Trade receivables	5 960	5 960
<b>Total non-current assets</b>	<b>35 296</b>	<b>35 762</b>
<b>Current assets</b>		
Inventories	4 849	5 190
Trade and other receivables	60 866	55 998
Treasury shares redeemed	11	8
Cash and cash equivalents	28	24
<b>Total current assets</b>	<b>65 754</b>	<b>61 220</b>
<b>Total assets</b>	<b>101 050</b>	<b>96 982</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	64 300	64 300
Reserves	9 172	9 172
Retained earnings	11 854	8 831
<b>Total</b>	<b>85 326</b>	<b>82 303</b>
<b>Non-current liabilities</b>		
Long-term loans	521	590
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	83	83
<b>Total non-current liabilities</b>	<b>1 912</b>	<b>1 981</b>
<b>Current liabilities</b>		
Trade and other liabilities	3 007	2 134
Short-term loans	9 778	9 784
Current portion of long-term loans	434	491
Current corporate income tax		78
Other tax liabilities	593	211
<b>Total current liabilities</b>	<b>13 812</b>	<b>12 698</b>
<b>Total liabilities</b>	<b>15 724</b>	<b>14 679</b>
<b>Total equity and liabilities</b>	<b>101 050</b>	<b>96 982</b>

Date of preparation: 23.04.2018

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of March 2018**

	<b>31.03.2018</b>	<b>31.03.2017</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	9 164	7 644
Other income		
<b>Total income</b>	<b>9 164</b>	<b>7 644</b>
Carrying amount of goods sold	(534)	(164)
Changes in inventories of finished products and work in progress	124	374
Materials and services	(3 585)	(3 051)
Personnel expenses	(870)	(782)
Depreciation / amortisation expenses	(879)	(729)
Other expenses	(82)	(26)
Finance income	5	7
Finance costs	(74)	(100)
<b>Total expenses</b>	<b>(5 895)</b>	<b>(4 471)</b>
<b>Profit before taxation</b>	<b>3 269</b>	<b>3 173</b>
Corporate income tax expense	(246)	(317)
<b>Profit/Loss for the period</b>	<b>3 023</b>	<b>2 856</b>
 <b>Total comprehensive income for the period</b>		
Earnings per share / in BGN per 1 share /	0.05	0.05

Date of preparation: 23.04.2018

Sofia

Prepared by:.....  
/ P. Moneva /

Executive Director:.....  
/ B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of March 2018**

	<b>31.03.2018</b>	<b>31.03.2017</b>
	<i><b>BGN'000</b></i>	<i><b>BGN'000</b></i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	6 463	7 873
Payments to suppliers of materials, goods and services	(2 906)	(3 222)
Payments to personnel	(795)	(709)
Payments of interest and dividends	(2)	(3)
Corporate income tax payments	(325)	(301)
Other proceeds / payments	(1 654)	(1 342)
<b><i>Net cash flows</i></b>	<b>781</b>	<b>2 296</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(588)	(824)
<b><i>Net cash flows</i></b>	<b>(588)</b>	<b>(824)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans		
Payments on loans		(1 174)
Payment of interest, dividends	(49)	(68)
Payments on finance lease	(137)	(240)
Other proceeds/payments	(3)	
<b><i>Net cash flows</i></b>	<b>(189)</b>	<b>(1 482)</b>
<hr/>		
<b>Change in cash and cash equivalents</b>	<b>4</b>	<b>(10)</b>
Cash and cash equivalents at the beginning of the period	24	50
Cash and cash equivalents at the end of the period	28	40

Date of preparation: 23.04.2018

Sofia

Prepared by:.....  
 / P. Moneva /

Executive

Director:.....

/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of March 2018**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2017</b>	<b>56 600</b>	<b>3 149</b>	<b>4 661</b>	<b>8 585</b>	<b>72 995</b>
Profit/loss for the period				8 831	8 831
Other comprehensive income		477			477
Including from tax effect of the revaluation of property, plant and equipment		(60)			(60)
<b>Total comprehensive income</b>		<b>477</b>		<b>8 831</b>	<b>9 308</b>
Issue of shares by the owners	7 700			(7 700)	
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves			885	(885)	
<b>Total amount of income and expenses recognised during the period</b>	<b>7 700</b>		<b>885</b>	<b>(8 585)</b>	
<b>Balance as of 31.12.2017</b>	<b>64 300</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
<b>Balance as of 01.01.2018</b>	<b>63 400</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
Profit/loss for the period				3 023	3 023
Other comprehensive income					
<b>Total comprehensive income</b>				<b>3 023</b>	<b>3 023</b>
Issue of shares by the owners					
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves					
<b>Total amount of income and expenses recognised during the period</b>					
<b>Balance as of 31.03.2018</b>	<b>63 400</b>	<b>3 626</b>	<b>5 546</b>	<b>11 854</b>	<b>85 326</b>

Date of preparation: 23.04.2018  
Sofia

Prepared by:.....  
/P. Moneva/

Executive Director:.....  
/B. Georgiev /